Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 3/20 | 0.31 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13216909 | 0.74 | ALDH1A1 (0.34) | MAPK1ATMALDH1A1LMNATHRB | |
| SCHEMBL13854014 | 0.70 | — | — | |
| SCHEMBL25606172 | 0.70 | CDC25A (0.35) | ALDH1A1LMNA | |
| SCHEMBL10487046 | 0.64 | MAPK1 (0.58) | MAPK1ATMALDH1A1LMNATHRB | |
| SCHEMBL23046254 | 0.62 | HPGD (0.36) | MAPK1ATMALDH1A1LMNATHRB | |
| SCHEMBL15739584 | 0.62 | HAAO (0.47) | FEN1ERCC5DAOALDH1A1LMNA | |
| SCHEMBL31136330 | 0.62 | TNKS (0.33) | ALDH1A1 | |
| SCHEMBL2714078 | 0.60 | FEN1 (0.39) | FEN1ERCC5ALDH1A1 | |
| SCHEMBL25604490 | 0.60 | KDM5A (0.37) | ALDH1A1LMNA | |
| SCHEMBL27295267 | 0.60 | KAT2B (0.34) | MAPK1ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170106106-A1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | UNIVERSITAT ZURICH (CH) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170106106-A1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | AOC1, XDH, FOLR1 | MAPK1 4237/4885ATM 3745/4885FEN1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.